🔗 Share this article

Given that the US undertakes historic adjustments to its vaccine guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by casting doubt on coronavirus shots during the global health crisis and has zeroed in on potential fatalities after COVID-19 immunization in her short tenure at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Program

Agency leaders were set to unveil major changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of alignment with many the world with insufficient data for benefit. This reveal has been pushed back until the new year.

In place of the top vaccines chief, Høeg is scheduled to address the audience at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to head the center this year.

A Shift at the Agency

The acting appointment may indicate a tighter collaboration between the drug and biologics branches as Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for halting some childhood shot schedules in the US so as to align more similar to the Danish model, a nation with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Background

Høeg has no apparent track record in drug development, approval processes or management, which has been customary for previous leaders of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who headed the center have had.”

CDER has an enormous portfolio at the FDA, she emphasized.

“The public just pays attention on the innovative therapies, but the off-patent medication office authorizes thousands of generic medications. There’s a biosimilars program, over-the-counter program and so forth, and every single one must be looked after,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to cause problems.”

There is also, a substantial management aspect to the position, which oversees over 5,000 personnel. “It is a huge administrative position, if you perform it correctly,” she added.

Agency Reaction and Controversial Policies

In response to concerns about Høeg’s fitness for the role and whether this selection indicates increased cooperation among agency officials on vaccines, a spokesperson responded that the “inquiries are based on inaccurate assumptions”.

“Her experience matches the duties of her role,” the spokesperson explained, pointing to the time Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a controversial rapid medication authorization process that reportedly troubled her former heads. “By what process are these medications being selected for this voucher program? Who makes the choices?” Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards less stringent rules of all drugs, except for shots.”

Established History on Immunizations

With immunizations, Høeg has a more documented, if concerning, history, Howard said. She published a research paper using non-validated volunteer-provided data to determine the incidence of heart inflammation after Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are more dangerous than they are.

Included in her “wish list” for the incoming administration included changing guidelines for new vaccines and halting “optional” vaccines, she stated post-election on a podcast. At the agency, Dr. Høeg has reportedly suggested excluding young men from obtaining Covid vaccinations.

“She is an all-around ideologue who begins with her beliefs and works backwards to accommodate the data in a highly deceptive, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|